Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod as Neo-adjuvant Treatment in Lentigo Malignant of the Face
NCT01720407Phase 3Completed
- Sponsor
- CHU de Nantes
- Start
- Dec 2012
- Primary completion
- Oct 2019
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of imiquimod in lentigo maligna (LM), sponsored by CHU de Nantes. Started Dec 2012; status: completed.
02
Drugs
imiquimod
03
Conditions
lentigo maligna (LM)
Beyond the preview
Go deeper on NCT01720407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01720407.